TARO News and Press, Taro Pharmaceutical Industries Ltd. From 10/24/22

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2022, after the close of market on Thursday, October 27, 2022. The release will be accessible on Taro’s website at www....

Stocks recorded another day of gains on Monday, extending an upswing that took place last week. Ongoing hope that the Federal Reserve will take a less hawkish stance overcame weak economic news out of China. Among individual stocks, Revlon ( REV ) expanded its value by almost a thir...

Taro Pharmaceutical ( NYSE: TARO ) on Monday hit a 52-week low of $32.50. The Israeli drugmaker, known for marking generic and over-the-counter products, is down ~28% year to date. Taro ( TARO ) beat on the top and bottom lines in its Q2 2022 results at the...

Taro Pharmaceuticals ( NYSE: TARO ) said it began a voluntary type 1 recall of six lots of bone disorder drug Taro-Zoledronic Acid injection as they may contain particulate matter over the specified requirements. The Israeli company said the recall was being conducted wi...

Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL vials. The reason for the recall is that product from these lots may contain particulate matter over the specified requirements...

Taro Pharmaceutical press release ( NYSE: TARO ): Q2 Non-GAAP EPS of $1.09 beats by $0.24 . Revenue of $156.7M (+6.5% Y/Y) beats by $6.8M . For further details see: Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2022. Quarter ended June 30, 2022* Highlights ─ compared to June 30, 2021 Net sales incre...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2022, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the close of market on Wednesday, July 27, 2022. The release will be accessible on Taro’s website at www.taro.com...

Based on the current long-term trend, shares look like they will test long-term support. We expect support to hold there based on the company's strong earnings power and clean balance sheet. Adjusted cash flow numbers also remain strong. Investors may need to buy the fear here whe...